IDEXX Laboratories, Inc. $IDXX is Fundsmith Investment Services LTD.’s 6th Largest Position

Fundsmith Investment Services LTD. lessened its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 19.5% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 553,859 shares of the company’s stock after selling 134,498 shares during the quarter. IDEXX Laboratories makes up about 6.9% of Fundsmith Investment Services LTD.’s portfolio, making the stock its 6th biggest holding. Fundsmith Investment Services LTD. owned 0.69% of IDEXX Laboratories worth $374,702,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. EverSource Wealth Advisors LLC increased its holdings in IDEXX Laboratories by 2.5% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 621 shares of the company’s stock worth $397,000 after acquiring an additional 15 shares in the last quarter. Harbour Investments Inc. increased its holdings in IDEXX Laboratories by 13.3% in the 4th quarter. Harbour Investments Inc. now owns 136 shares of the company’s stock worth $92,000 after acquiring an additional 16 shares in the last quarter. CWA Asset Management Group LLC increased its holdings in IDEXX Laboratories by 3.5% in the 4th quarter. CWA Asset Management Group LLC now owns 509 shares of the company’s stock worth $344,000 after acquiring an additional 17 shares in the last quarter. Stratos Wealth Partners LTD. increased its holdings in IDEXX Laboratories by 1.7% in the 3rd quarter. Stratos Wealth Partners LTD. now owns 1,069 shares of the company’s stock worth $683,000 after acquiring an additional 18 shares in the last quarter. Finally, Cary Street Partners Investment Advisory LLC increased its holdings in IDEXX Laboratories by 11.5% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 174 shares of the company’s stock worth $111,000 after acquiring an additional 18 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Price Performance

IDEXX Laboratories stock opened at $573.00 on Wednesday. IDEXX Laboratories, Inc. has a 52-week low of $506.91 and a 52-week high of $769.98. The firm has a market capitalization of $45.20 billion, a price-to-earnings ratio of 42.19, a PEG ratio of 3.12 and a beta of 1.55. The company has a fifty day simple moving average of $563.14 and a 200-day simple moving average of $624.14. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The business had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.12 billion. During the same quarter in the prior year, the firm earned $2.91 earnings per share. The company’s revenue for the quarter was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, equities analysts anticipate that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently commented on IDXX shares. Wall Street Zen raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Saturday. Weiss Ratings lowered shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 11th. Stifel Nicolaus dropped their target price on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a report on Tuesday, March 31st. Citigroup began coverage on shares of IDEXX Laboratories in a report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 target price for the company. Finally, UBS Group dropped their target price on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a report on Tuesday, April 28th. Seven investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and a consensus price target of $751.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.